Arrhythmia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:32:25 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Arrhythmia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Flecainide to Reduce Risk of Atrial Arrhythmia After Patent Foramen Ovale Closure in Patients https://clinicaltrials.eu/trial/study-on-flecainide-to-reduce-risk-of-atrial-arrhythmia-after-patent-foramen-ovale-closure-in-patients/ Wed, 29 Apr 2026 14:29:05 +0000 https://clinicaltrials.eu/trial/study-on-flecainide-to-reduce-risk-of-atrial-arrhythmia-after-patent-foramen-ovale-closure-in-patients/ This clinical trial is focused on studying the effects of a medication called Flecainide on patients who have undergone a procedure known as Patent Foramen Ovale (PFO) closure. A PFO is a small opening in the heart that didn’t close the way it should after birth. The study is particularly interested in patients who might experience Atrial Arrhythmia or Tachycardia after this procedure. Atrial Arrhythmia refers to irregular heartbeats, while Tachycardia is a condition where the heart beats faster than normal.

The purpose of the study is to determine if Flecainide can help prevent these irregular heartbeats during the first three months after the PFO closure. Participants in the study will be monitored for any episodes of irregular heartbeats, both those that cause symptoms and those that do not. This monitoring will be done using a small device called an Insertable Cardiac Monitor (ICM), which keeps track of the heart’s activity over a long period.

The study will last for several months, with participants being observed for any heart-related issues, such as palpitations, strokes, or the need for unexpected medical visits. The researchers will also look at the overall health of the participants and any side effects related to Flecainide. The goal is to gather information on how effective and safe Flecainide is in reducing the risk of heart rhythm problems after PFO closure.

]]> Study of flecainide alone or with beta-blockers or calcium channel blockers and quinidine for treating ventricular arrhythmias in patients with Andersen-Tawil syndrome and MEPPC https://clinicaltrials.eu/trial/study-on-flecainide-and-drug-combination-for-ventricular-arrhythmias-in-patients-with-andersen-tawil-syndrome-and-multifocal-ectopic-purkinje-related-premature-contractions/ Wed, 29 Apr 2026 14:28:34 +0000 https://clinicaltrials.eu/trial/study-on-flecainide-and-drug-combination-for-ventricular-arrhythmias-in-patients-with-andersen-tawil-syndrome-and-multifocal-ectopic-purkinje-related-premature-contractions/ This study focuses on two rare heart conditions: Andersen-Tawil syndrome and Multifocal Ectopic Purkinje-related Premature Contractions. These conditions cause irregular heartbeats that originate from specific areas of the heart. The study aims to find the most effective treatment for controlling abnormal heart rhythms in patients with these conditions.

The study will test several medications including flecainide, which will be used alone or in combination with other heart medications. These additional medications include beta-blockers (bisoprolol, metoprolol, nebivolol, propranolol, atenolol) and calcium channel blockers like verapamil. For patients with Multifocal Ectopic Purkinje-related Premature Contractions, the medication quinidine will also be tested.

During the study, participants will take different combinations of these medications for specific periods. The medications will be given as oral tablets, and the treatment will continue for several weeks to determine which combination works best for each individual patient in controlling their irregular heart rhythms.

]]>